Published in Proc Natl Acad Sci U S A on July 01, 1988
Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1989) 12.54
Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A (1991) 10.05
Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J Virol (1989) 5.15
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Properties of avian retrovirus particles defective in viral protease. J Virol (1990) 4.03
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol (1998) 3.84
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J (1989) 3.50
Functional domains of the capsid protein of human immunodeficiency virus type 1. J Virol (1994) 3.47
Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J Virol (1992) 3.44
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes. Microbiol Rev (1993) 3.33
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A (1995) 3.18
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol (1993) 2.96
Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proc Natl Acad Sci U S A (1991) 2.80
TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother (2005) 2.76
Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles. J Virol (1993) 2.69
Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J Virol (1991) 2.65
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
Role of the gag polyprotein precursor in packaging and maturation of Rous sarcoma virus genomic RNA. J Virol (1990) 2.39
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection. Proc Natl Acad Sci U S A (1990) 2.32
Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A (2001) 2.32
The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J Virol (1996) 2.31
Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc Natl Acad Sci U S A (1991) 2.28
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein. J Virol (1991) 2.23
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol (1996) 2.22
The nonmyristylated Pr160gag-pol polyprotein of human immunodeficiency virus type 1 interacts with Pr55gag and is incorporated into viruslike particles. J Virol (1992) 2.17
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1991) 2.16
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother (1998) 1.92
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol (1990) 1.83
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol (1995) 1.81
Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc Natl Acad Sci U S A (1989) 1.81
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol (1994) 1.80
Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J Virol (1995) 1.78
A replication-deficient HIV-1 DNA used for quantitation of the polymerase chain reaction (PCR). Nucleic Acids Res (1990) 1.76
Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol (1996) 1.71
Mutational analysis of human immunodeficiency virus type 1 protease suggests functional homology with aspartic proteinases. J Virol (1989) 1.66
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol (2004) 1.65
Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.61
Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc Natl Acad Sci U S A (1989) 1.60
Identification and characterization of human immunodeficiency virus type 1 gag-pol fusion protein in transfected mammalian cells. J Virol (1991) 1.55
Human immunodeficiency virus type 1 protease cleaves the intermediate filament proteins vimentin, desmin, and glial fibrillary acidic protein. Proc Natl Acad Sci U S A (1990) 1.55
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol (2005) 1.53
Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci (2000) 1.52
Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Natl Acad Sci U S A (1994) 1.50
Proteolytic processing of Ty3 proteins is required for transposition. J Virol (1993) 1.49
Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev (1995) 1.49
Target repurposing for neglected diseases. Future Med Chem (2011) 1.48
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. Proc Natl Acad Sci U S A (1989) 1.47
Targeting structural flexibility in HIV-1 protease inhibitor binding. Drug Discov Today (2006) 1.46
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
Domains upstream of the protease (PR) in human immunodeficiency virus type 1 Gag-Pol influence PR autoprocessing. J Virol (1995) 1.45
Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2002) 1.45
The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process. J Virol (2002) 1.45
Effect of the active site D25N mutation on the structure, stability, and ligand binding of the mature HIV-1 protease. J Biol Chem (2008) 1.44
The challenge of developing robust drugs to overcome resistance. Drug Discov Today (2011) 1.43
Bovine leukemia virus RNA sequences involved in dimerization and specific gag protein binding: close relation to the packaging sites of avian, murine, and human retroviruses. J Virol (1993) 1.43
Stability and activity of human immunodeficiency virus protease: comparison of the natural dimer with a homologous, single-chain tethered dimer. Proc Natl Acad Sci U S A (1990) 1.40
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
Effect of linker insertion mutations in the human immunodeficiency virus type 1 gag gene on activation of viral protease expressed in bacteria. J Virol (1993) 1.37
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus protease. Proc Natl Acad Sci U S A (1988) 1.36
Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A (2009) 1.34
Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1991) 1.33
Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release. J Virol (1998) 1.32
Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 1.31
Growing applications of "click chemistry" for bioconjugation in contemporary biomedical research. Cancer Biother Radiopharm (2009) 1.30
Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain. J Virol (1994) 1.30
Motions on the millisecond time scale and multiple conformations of HIV-1 capsid protein: implications for structural polymorphism of CA assemblies. J Am Chem Soc (2012) 1.28
Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir. AIDS Rev (2008) 1.26
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein. J Virol (1999) 1.25
SC-52151, a novel inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1995) 1.25
Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells. Antimicrob Agents Chemother (1992) 1.24
Copper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanisms. Proc Natl Acad Sci U S A (1991) 1.24
Retroviral protease-like gene in the vaccinia virus genome. Proc Natl Acad Sci U S A (1989) 1.24
Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J Exp Med (2002) 1.23
Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. J Virol (1997) 1.22
Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J Virol (1992) 1.21
Two types of virus-related particles are found during transmissible gastroenteritis virus morphogenesis. J Virol (1998) 1.21
HIV-1 protease with 20 mutations exhibits extreme resistance to clinical inhibitors through coordinated structural rearrangements. Biochemistry (2012) 1.20
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol (1986) 37.70
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci U S A (1979) 21.22
Nucleotide sequence of the AIDS virus, LAV. Cell (1985) 16.81
Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus. Nature (1985) 12.08
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature (1988) 10.69
Classification of human colorectal adenocarcinoma cell lines. Cancer Res (1976) 7.00
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science (1985) 6.31
A deletion mutation in the 5' part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol (1985) 5.78
Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci U S A (1985) 5.36
A structural model for the retroviral proteases. Nature (1987) 4.78
Murine leukemia virus maturation: protease region required for conversion from "immature" to "mature" core form and for virus infectivity. Virology (1985) 4.65
Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci U S A (1987) 3.72
Virus-specific precursor polypeptides in cells infected with Rauscher leukemia virus: synthesis, identification, and processing. Virology (1976) 3.26
"gag" polyprotein precursors of Rauscher murine leukemia virus. Virology (1977) 2.95
In vitro cleavage of avian retrovirus gag proteins by viral protease p15. Virology (1979) 2.64
Translational readthrough of an amber termination codon during synthesis of feline leukemia virus protease. J Virol (1985) 2.53
Bovine leukemia virus protease: purification, chemical analysis, and in vitro processing of gag precursor polyproteins. J Virol (1986) 2.28
Molecular characterization of a polymerase mutant human immunodeficiency virus. Virology (1987) 1.76
Amino acid sequence of p15 from avian myeloblastosis virus complex. Biochemistry (1981) 1.58
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
Primary structure, gene organization and polypeptide expression of poliovirus RNA. Nature (1981) 16.61
Mechanism of activation of a human oncogene. Nature (1982) 12.09
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med (1997) 10.62
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 10.13
Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 9.92
B.M.A. deputizing service in Sheffield, 1970. Br Med J (1973) 9.83
Signals and transduction mechanisms for activation of plant defenses against microbial attack. Cell (1989) 9.42
Fine-structure mapping and functional analysis of temperature-sensitive mutants in the gene encoding the herpes simplex virus type 1 immediate early protein VP175. J Virol (1980) 9.30
Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol (1982) 8.88
BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humans. Antimicrob Agents Chemother (1981) 8.81
The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature (1981) 8.44
Helper-independent transformation by unintegrated Harvey sarcoma virus DNA. J Virol (1978) 7.75
Activation tagging in Arabidopsis. Plant Physiol (2000) 7.09
Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature (1986) 7.06
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
"Practis". (General) Practice Recording and Computer Terminal Information System. J R Coll Gen Pract (1969) 6.99
Nitric oxide functions as a signal in plant disease resistance. Nature (1998) 6.94
Whole-genome association study of bipolar disorder. Mol Psychiatry (2008) 6.80
Induction of murine C-type viruses from clonal lines of virus-free BALB-3T3 cells. Science (1971) 6.71
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 6.45
Activation tagging identifies a conserved MYB regulator of phenylpropanoid biosynthesis. Plant Cell (2000) 6.12
Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol (1985) 5.73
Cloning of bovine GAP and its interaction with oncogenic ras p21. Nature (1988) 5.56
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Reactive oxygen intermediates mediate a systemic signal network in the establishment of plant immunity. Cell (1998) 5.46
ras-Related gene sequences identified and isolated from Saccharomyces cerevisiae. Nature (1984) 5.32
Studies on the nucleic acid sequences of Kirsten sarcoma virus: a model for formation of a mammalian RNA-containing sarcoma virus. J Virol (1973) 5.28
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
RNA in mammalian sarcoma virus transformed nonproducer cells homologous to murine leukemia virus RNA. Virology (1973) 5.04
Transfection of molecularly cloned Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J Virol (1980) 4.91
Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (1989) 4.80
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
The transforming proteins of Rous sarcoma virus, Harvey sarcoma virus and Abelson virus contain tightly bound lipid. Cell (1982) 4.66
Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. J Virol (1980) 4.63
cDNA for the human beta 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A (1987) 4.61
Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol (1981) 4.54
Use it or lose it: engaged lifestyle as a buffer of cognitive decline in aging? Psychol Aging (1999) 4.45
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Guanine nucleotide-binding and autophosphorylating activities associated with the p21src protein of Harvey murine sarcoma virus. Nature (1980) 4.43
Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 4.35
Guanine nucleotide-binding activity as an assay for src protein of rat-derived murine sarcoma viruses. Proc Natl Acad Sci U S A (1979) 4.34
Rapid transient induction of phenylalanine ammonia-lyase mRNA in elicitor-treated bean cells. Proc Natl Acad Sci U S A (1985) 4.30
Requirement of either of a pair of ras-related genes of Saccharomyces cerevisiae for spore viability. Nature (1984) 4.23
Controlled trial of oxprenolol and practolol in hypertension. Br Med J (1970) 4.23
Salicylic acid potentiates an agonist-dependent gain control that amplifies pathogen signals in the activation of defense mechanisms. Plant Cell (1997) 4.08
Harvey sarcoma virus: a second murine type C sarcoma virus with rat genetic information. J Virol (1974) 3.92
Molecular cloning of the Harvey sarcoma virus closed circular DNA intermediates: initial structural and biological characterization. J Virol (1979) 3.90
Phytoalexins: enzymology and molecular biology. Adv Enzymol Relat Areas Mol Biol (1983) 3.89
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
Activation, structure, and organization of genes involved in microbial defense in plants. Adv Genet (1990) 3.78
Stress Responses in Alfalfa (Medicago sativa L.): X. Molecular Cloning and Expression of S-Adenosyl-l-Methionine:Caffeic Acid 3-O-Methyltransferase, a Key Enzyme of Lignin Biosynthesis. Plant Physiol (1991) 3.76
Separation of murine cellular and murine leukaemia virus DNA polymerases. Nat New Biol (1971) 3.71
Friend strain of spleen focus-forming virus: a recombinant between mouse type C ecotropic viral sequences and sequences related to xenotropic virus. J Virol (1977) 3.70
Elicitor rapidly induces chalcone synthase mRNA in Phaseolus vulgaris cells at the onset of the phytoalexin defense response. Proc Natl Acad Sci U S A (1984) 3.63
Friend strain of spleen focus-forming virus is a recombinant between ecotropic murine type C virus and the env gene region of xenotropic type C virus. Proc Natl Acad Sci U S A (1977) 3.62
The Cpx two-component signal transduction pathway of Escherichia coli regulates transcription of the gene specifying the stress-inducible periplasmic protease, DegP. Genes Dev (1995) 3.61
Abnormal plant development and down-regulation of phenylpropanoid biosynthesis in transgenic tobacco containing a heterologous phenylalanine ammonia-lyase gene. Proc Natl Acad Sci U S A (1990) 3.60
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effects. Proc Natl Acad Sci U S A (1986) 3.59
A plant homolog of the neutrophil NADPH oxidase gp91phox subunit gene encodes a plasma membrane protein with Ca2+ binding motifs. Plant Cell (1998) 3.55
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. J Biol Chem (1989) 3.51
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Functional organization of the simian virus 40 origin of DNA replication. Mol Cell Biol (1986) 3.40
Structure and function of G protein-coupled receptors. Annu Rev Biochem (1994) 3.36
Priming for and induction of anti-poliovirus neutralizing antibodies by synthetic peptides. Nature (1983) 3.35
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci U S A (1994) 3.33
Separation of sarcoma virus-specific and leukemia virus-specific genetic sequences of Moloney sarcoma virus. Proc Natl Acad Sci U S A (1975) 3.28
Radioimmunoassay of mammalian type C viral proteins. I. Species specific reactions of murine and feline viruses. J Immunol (1972) 3.23
Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol (1981) 3.18
Modern obstetrics and the general practitioner. Br Med J (1975) 3.15
Guanidine-selected mutants of poliovirus: mapping of point mutations to polypeptide 2C. J Virol (1986) 3.15
Identification of effector residues and a neutralizing epitope of Ha-ras-encoded p21. Proc Natl Acad Sci U S A (1986) 3.11
Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. J Biol Chem (1988) 3.10
Dissection of malonyl-coenzyme A decarboxylation from polyketide formation in the reaction mechanism of a plant polyketide synthase. Biochemistry (2000) 3.05
Mammalian and yeast ras gene products: biological function in their heterologous systems. Science (1985) 3.03
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group. N Engl J Med (1993) 2.98
p21 of Kirsten murine sarcoma virus is thermolabile in a viral mutant temperature sensitive for the maintenance of transformation. J Virol (1979) 2.94
Anaesthetic services to dental patients: England and Wales, 1976. Br Dent J (1978) 2.93
Comparative biochemical properties of p21 ras molecules coded for by viral and cellular ras genes. J Virol (1982) 2.91
Radioimmunoassay of mammalian type-C viral proteins: interspecies antigenic reactivities of the major internal polypeptide. Proc Natl Acad Sci U S A (1972) 2.90